Skip to main content

Table 3 Bispecific antibodies targeting CD47 and other molecular targets

From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Code

Company/Research Team

Target

Structure

IgG subclass

Format

NI-1701 (TG-1801)a

LightChain bioscience/TG Therapeutics

CD47 × CD19

Fab+Fab with Fc, 1 + 1, κλ

IgG1

one antibody arm (kappa) specific for CD47 and a second arm (lambda) specific to CD19, mesothelin or tumor associated antigen

IMM-0306a

ImmuneOnco Biopharma

CD47 × CD20

ligand+Fab with Fc, 2 + 2

IgG1

SIRPα V2-D1 infused with amino terminal of heavy chain of Rituximab

DVD-Ig SL/LL

Ravindra Majeti’s lab in Stanford University

CD47 × CD20

DVD-IgG

IgG1

The amino terminus of each B6H12 variable domain infused to the carboxyl terminus of each 2B8 with linker”TVAAP”

SIRPa-gamma-CD20 HC

CD47 × CD20

ligand+IgG

IgG1

ligand located in Fab domain of intact aCD20 antibody(2B8, Rituximab)

CD20-2GL-SIRPa HC; CD20-4GL-SIRPa HC

CD47 × CD20

ligand+IgG

IgG1

ligand located in Fc domain of intact aCD20 antibody(2B8, Rituximab)

bi-scFv RTX-CD47

Wijnand Helfrich’s lab in Wijnand Helfrich

CD47 × CD20

ScFV+ScFv,1 + 1

NA

CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv

LQ007

Novamab

CD47 × CD20

nanobody (C terminal) + IgG

IgG4

nanobody from camel was fused to the carboxyl terminus of Rituximab

HMBD-004A

Hummingbird bioscience

CD47 × CD33

Fab+Fab with Fc, 1 + 1

IgG1

Humanized anti-CD47 variable domain as an effector arm and the gemtuzumab variable domain as an anti-CD33 or BCMA specificity arm.

HMBD-004B

Hummingbird bioscience

CD47 × BCMA

Fab+Fab with Fc, 1 + 1

IgG1

NI-1801a

Light Chain bioscience (Novimmune SA)

CD47 × MSLN

Fab+Fab with Fc,1 + 1,κλ

IgG1

one arm target to CD47(kappa) and the other arm target to (lambda) mesothelin or tumor associated antigen

NI-2401

Light Chain bioscience (Novimmune SA)

CD47 × TAA

Fab+Fab with Fc,1 + 1,κλ

Not Disclosed

NI-2601

Light Chain bioscience (Novimmune SA)

CD47 × TAA

Fab+Fab with Fc,1 + 1,κλ

Not Disclosed

PT-886

Phanes Therapeutics

CD47 × CLDN18.2

Fab+Fab with Fc, 1 + 1

Not Disclosed

Not Disclosed

PT-796

Phanes Therapeutics

CD47 × FRα

Fab+Fab with Fc, 1 + 1

Not Disclosed

Not Disclosed

PT-217

Phanes Therapeutics

CD47 × DLL3

Fab+Fab with Fc, 1 + 1

Not Disclosed

Not Disclosed

IMM-26011

ImmuneOnco Biopharma

CD47 × FLT-3

ligand+Fab with Fc, 2 + 2

IgG1

SIRPa V2-D1 linked

IMM-2902

ImmuneOnco Biopharma

CD47 × Her2

ligand+Fab with Fc,2 + 2

IgG1

SIRPa V2-D1 linked through a GS linker to amino terminal of light chain coding sequence of Herceptin (Trastuzumab)

SG3847

SUMGEN BIOTECH

CD47 × CD38

ligand+Fab with Fc, 2 + 2

IgG1

SIRPa V1-D1 linked through a GS linker to amino terminal of light chain coding sequence of

HX-009a

HanX Biopharmaceuticals

CD47 × PD-1

ligand +Fab with Fc, 2 + 2

IgG4

amino terminal of extracellular region ligand (SIRPA V2D1) infused with carboxyl terminus of anti PD1 antibody (HX008)

IBI-322a

Innovent

CD47 × PD-L1

Fab+nanobody with Fc,1 + 2

Not Disclosed

one arm target CD47 (Fab from IBI188), the other target is PDL1 (Bivalent nanobody)

BH-29XX

Hanmi Pharmaceutical

CD47 × PD-L1

Fab+Fab with Fc, 1 + 1

Not Disclosed

Not Disclosed

?

GenSci

CD47 × PD-L1

Fab+Fv, KIH, 1 + 1

Not Disclosed

one arm target CD47 (Fab from GenSci-059), the other target is PDL-1(Fv from GenSci-047)

PMC-122

PharmAbcine

CD47 × PD-L1

Not Disclosed

Not Disclosed

Unknown

ABP-160

Abpro Therapeutics

CD47 × PD-L1

Not Disclosed

IgG1 wt

Unknown

IMM-2505

ImmuneOnco Biopharma

CD47 × PD-L1

ligand+Fab with Fc, 2 + 2

IgG1

SIRPa V2-D1 infused with amino terminal of heavy chain of antiPDL-1 antibody (Atezolizumab?)

TJ-L1C4

I-MAB Biopharma

CD47 × PD-L1

Not Disclosed

Not Disclosed

PD-L1 antibody acts as the backbone and is linked with CD47 antibody

IAB

Sinomab

CD47× PD-L1

CV1(ALX148) + Fab with Fc

IgG1/IgG4

variable region of atezolizumab and consensus variant 1 (CV1) monomer

SL-172154a

Shattuck Labs

CD47× CD40

ligand+ligand with Fc, 1 + 1

IgG1

ECDs of SIRPα and CD 40 L, adjoined by a central domain termed SIRPα-Fc-CD 40 L.

DSP107

Kahr Medical

CD47 × 41BB

ligand+ligand with Fc, 1 + 1

IgG1

human soluble SIRPα and 4-1BBL

TJ C4GM

I-MAB Biopharma

CD47 × CSF-2R

IgG + fusion protein

IgG1 or G4

Human GM-CSF was fused to the heavy chain C terminus of CD47 antibody

IMM-0207

ImmuneOnco Biopharma

CD47× VEGF

ligand+receptor with Fc, 2 + 2

IgG1

SIRPa V2-D1 linked via an Fc fragment of an Ig to an Ig region of an extracellular domain of VEGFR1D

  1. aantibody in clinical trial